¼¼°èÀÇ ¸ÖƼ¿À¹Í½º ½ÃÀå
Multiomics
»óǰÄÚµå : 1787200
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 209 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¸ÖƼ¿À¹Í½º ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 74¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

¼¼°èÀÇ ¸ÖƼ¿À¹Í½º ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 29¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024-2030³â¿¡ CAGR 16.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 74¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¹úÅ© ¸ÖƼ¿À¹Í½º´Â CAGR 17.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 51¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ÜÀϼ¼Æ÷ ¸ÖƼ¿À¹Í½º ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR·Î 14.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 6,910¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 15.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸ÖƼ¿À¹Í½º ½ÃÀåÀº 2024³â¿¡ 7¾ï 6,910¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 11¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2024-2030³â CAGRÀº 15.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 15.5%¿Í 14.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 12.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¸ÖƼ¿À¹Í½º ½ÃÀå : ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ °³¿ä

¸ÖƼ¿À¹Í½º´Â »ý¹°ÇÐÀû ÀλçÀÌÆ®¿Í Á¤¹ÐÀǷḦ ¾î¶»°Ô ÀçÁ¤ÀÇÇϰí Àִ°¡?

À¯ÀüüÇÐ, Àü»çüÇÐ, ´Ü¹éÁúüÇÐ, ÈļºÀ¯ÀüüÇÐ, ´ë»çüÇÐÀ» °áÇÕÇÑ ÅëÇÕÀû Á¢±Ù¹ýÀÎ ¸ÖƼ¿À¹Í½º´Â »ý¹°ÇÐ ¿¬±¸¿Í ÀÓ»ó Àû¿ë¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ¸ÖƼ¿À¹Í½º´Â ¿©·¯ »ý¹°Ãþ¿¡ °ÉÄ£ ¹æ´ëÇÑ µ¥ÀÌÅͼ¼Æ®¸¦ Ȱ¿ëÇÔÀ¸·Î½á º¹ÀâÇÑ Áúº´, »ý¹°ÇÐÀû ±â´É, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ´õ ±íÀº ÀÌÇØ¸¦ Á¦°øÇÕ´Ï´Ù. ½ÃÄö½Ì ±â¼ú°ú °í󸮷® ºÐ¼® µµ±¸ÀÇ ¹ßÀüÀ¸·Î ¿¬±¸ÀÚµéÀº ´Ù¾çÇÑ ºÐÀÚ ¼ººÐ °£ÀÇ »óÈ£ ÀÛ¿ëÀ» Àü·Ê ¾ø´Â Á¤¹Ðµµ·Î Á¶»çÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¸Ó½Å·¯´×°ú ÀΰøÁö´ÉÀÇ ÅëÇÕÀº ¸ÖƼ¿À¹Í½º µ¥ÀÌÅÍÀÇ ÇØ¼®À» ´õ¿í °¡¼ÓÈ­ÇÏ¿© ¹ÙÀÌ¿À¸¶Ä¿ ¹ß°ß, Áúº´ Áø´Ü ¹× Ä¡·á °³ÀÔ¿¡ ȹ±âÀûÀÎ ¹ßÀüÀ» °¡Á®¿À°í ÀÖ½À´Ï´Ù. Á¾¾çÇп¡¼­ ¸ÖƼ¿À¹Í½º´Â Á¾¾çÀÇ ÀÌÁú¼ºÀ» ¹àÇô³»¾î º¸´Ù Ç¥ÀûÈ­µÈ Ä¡·á ¿ä¹ýÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î ¾ËÃ÷ÇÏÀ̸Ӻ´À̳ª ÆÄŲ½¼º´°ú °°Àº ½Å°æÅðÇ༺ Áúȯ¿¡¼­µµ ¸ÖƼ¿À¹Í½º´Â À¯ÀüÀû, ´ë»çÀû ¹è°æÀ» ¹àÈ÷´Â ½Ã½ºÅÛ»ý¹°ÇÐÀû Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Á¦¾à ¾÷°è´Â ½Å¾à°³¹ß °­È­, ÀÓ»ó½ÃÇèÀÇ °èÃþÈ­ ÃÖÀûÈ­, Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ ¹ÝÀÀ ¿¹ÃøÀ» À§ÇØ ¸ÖƼ¿À¹Í½º¸¦ Àû±Ø µµÀÔÇϰí ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ°ú ÷´Ü »ý¹°Á¤º¸ÇÐ µµ±¸ÀÇ µîÀåÀ¸·Î ¸ÖƼ¿À¹Í½º µ¥ÀÌÅ͸¦ ´ë±Ô¸ð·Î ÀúÀå, ºÐ¼®, ÇØ¼®ÇÒ ¼ö ÀÖ´Â ´É·ÂÀÌ Å©°Ô Çâ»óµÇ¾î Àü ¼¼°è ¿¬±¸ÀÚµéÀÌ º¸´Ù ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¤ºÎ ¹× ÀÇ·á ±â°üµéÀº Áß°³¿¬±¸¸¦ °¡¼ÓÈ­ÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» ÀνÄÇÏ°í ´ë±Ô¸ð ¸ÖƼ¿À¹Í½º ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀü¿¡µµ ºÒ±¸Çϰí, ÀÌ ºÐ¾ß´Â µ¥ÀÌÅÍ Á¶È­, Ç¥ÁØÈ­, µ¥ÀÌÅÍ °øÀ¯¿¡ ´ëÇÑ À±¸®Àû °í·Á¿Í °ü·ÃµÈ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, °è»ê»ý¹°Çаú µ¥ÀÌÅÍ ÅëÇÕ ÇÁ·¹ÀÓ¿öÅ©ÀÇ ²÷ÀÓ¾ø´Â Çõ½ÅÀ¸·Î ¸ÖƼ¿À¹Í½º´Â Á¤¹ÐÀÇ·á¿Í Áúº´ ¿¹¹æ Àü·«¿¡ º¯È­¸¦ °¡Á®¿Ã Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

¸ÖƼ¿À¹Í½ºÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖ´Â »õ·Î¿î ÀÀ¿ë ºÐ¾ß¿Í »ê¾÷Àº?

¸ÖƼ¿À¹Í½º´Â Á¤¹ÐÀÇ·á¿¡¼­ÀÇ ¿ªÇÒ ¿Ü¿¡µµ ³ó¾÷, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸, ¿µ¾ç°úÇÐ, ȯ°æ ¸ð´ÏÅ͸µ µî ´Ù¾çÇÑ ºÐ¾ß¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ³ó¾÷ ºÐ¾ß¿¡¼­ ¸ÖƼ¿À¹Í½º´Â ÀÛ¹°ÀÇ È¸º¹·ÂÀ» ³ôÀ̰í, Åä¾ç ¹Ì»ý¹°À» °³¼±Çϸç, ±âÈÄ º¯È­·Î ÀÎÇÑ ½ºÆ®·¹½º ¿äÀÎÀ» °ßµô ¼ö ÀÖ´Â À¯ÀüÀûÀ¸·Î ¿ì¼öÇÑ ½Ä¹° ǰÁ¾À» °³¹ßÇϱâ À§ÇØ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸´Â Àΰ£ °Ç°­, ³ó¾÷, »ê¾÷ »ý¸í°øÇÐÀÇ º¹ÀâÇÑ ¹Ì»ý¹° »óÈ£ÀÛ¿ë ¿¬±¸¿¡ ¸ÖƼ¿À¹Í½º¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¸ÞŸÀ¯Àüü, ´Ü¹éÁúüÇÐ, ´ë»çüÇÐÀ» Àå³» ¼¼±ÕÃÑ ¿¬±¸¿¡ Àû¿ëÇÔÀ¸·Î½á Àå³» ¹Ì»ý¹° ±¸¼º°ú ºñ¸¸, ´ç´¢, ¿°Áõ¼º Áúȯ µîÀÇ Áúº´°úÀÇ ¿¬°ü¼ºÀ» ±Ô¸íÇϴ ȹ±âÀûÀÎ ¹ß°ßÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù. ¿µ¾çÇп¡¼­ ¸ÖƼ¿À¹Í½º´Â °³ÀÎÀÇ À¯ÀüÀû, ´ë»çÀû ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó °³ÀÎÈ­µÈ ½Ä´ÜÀ» ÃßõÇÏ´Â ¿µ¾çÀ¯ÀüüÇзÎÀÇ ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ½ÄÀ½·á »ê¾÷¿¡¼­´Â ¹ßÈ¿ °øÁ¤ ÃÖÀûÈ­, ÇÁ·Î¹ÙÀÌ¿Àƽ½º ó¹æ °³¼±, °í±Þ ¹Ì»ý¹° ÇÁ·ÎÆÄÀϸµÀ» ÅëÇÑ ½Äǰ ¾ÈÀü¼º È®º¸¸¦ À§ÇØ ¸ÖƼ¿À¹Í½º°¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÖƼ¿À¹Í½º´Â »ýŰèÀÇ »ý¹° ´Ù¾ç¼º ¸ð´ÏÅ͸µ, ¿À¿°ÀÇ ¿µÇâ ÃßÀû, ½ÉÇØ ¿­¼öºÐÃⱸ¿Í °°Àº ±ØÇÑ È¯°æ¿¡¼­ÀÇ ¹Ì»ý¹° ±ºÁý Á¶»ç µîÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ȯ°æ°úÇп¡µµ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. µ¶¼ºÇÐ ºÐ¾ß¿¡¼­´Â ºÐÀÚ ¼öÁØ¿¡¼­ È­ÇÐÁ¦Ç° ³ëÃâÀ» ÀÌÇØÇϱâ À§ÇØ ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀÌ Á¡Á¡ ´õ ÅëÇյǰí ÀÖÀ¸¸ç, À§Çè Æò°¡ ¹× ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÇÕ¼º»ý¹°ÇÐÀÇ ¹ßÀü°ú ÇÔ²² ¸ÖƼ¿À¹Í½º´Â »õ·Î¿î ¹ÙÀÌ¿À¼ÒÀç, ¹ÙÀÌ¿À¿¬·á, ¹ÙÀÌ¿ÀÀǾàǰÀÇ ¿£Áö´Ï¾î¸µÀ» ÃËÁøÇÏ°í ±× »ê¾÷Àû Àǹ̸¦ ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù. ¸ÖƼ¿À¹Í½ºÀÇ ´ÙÇÐÁ¦Àû äÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ÀüÅëÀûÀÎ »ý¹° ÀÇÇÐ ¿¬±¸ÀÇ Æ²À» ³Ñ¾î Çõ½ÅÀ» ÃËÁøÇÏ°í °úÇÐ ¹× »ó¾÷ ºÎ¹®¿¡ º¯È­¸¦ °¡Á®¿Ã ¼ö ÀÖ´Â ¿µÇâ·ÂÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¸ÖƼ¿À¹Í½º µ¥ÀÌÅÍ ÅëÇÕÀÌ ¹Ì·¡ÀÇ °úÇÐÀû Çõ½Å¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀϱî?

¸ÖƼ¿À¹Í½º µ¥ÀÌÅͼ¼Æ®ÀÇ ÅëÇÕÀº ÀÌ ºÐ¾ß¿¡¼­ °¡Àå µµÀüÀûÀ̸鼭µµ ¹Ì·¡ÁöÇâÀûÀÎ °úÁ¦ Áß ÇϳªÀÔ´Ï´Ù. ¸ÖƼ¿À¹Í½º ¿¬±¸¿¡¼­ »ý¼ºµÇ´Â ¹æ´ëÇÑ ¾çÀÇ µ¥ÀÌÅÍ´Â ¼­·Î ´Ù¸¥ »ý¹°ÇÐÀû °èÃþÀ» ³Ñ³ªµé¸ç ÀλçÀÌÆ®¸¦ ÅëÇÕÇÒ ¼ö ÀÖ´Â °í±Þ °è»ê ¸ðµ¨ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÃÖ±Ù AI ±â¹Ý ºÐ¼®, Çù¾÷ ÇнÀ, ³×Æ®¿öÅ© ±â¹Ý ¸ðµ¨¸µÀÇ ¹ßÀüÀº ¸ÖƼ¿À¹Í½º µ¥ÀÌÅÍ À¶ÇÕÀ» °³¼±ÇÏ°í º¸´Ù °­·ÂÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ¹ß°ß°ú Áúº´ ¸ðµ¨¸µÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ÆÄÀÌÇÁ¶óÀÎÀÇ Ç¥ÁØÈ­¿Í ¿ÀÇ ¾×¼¼½º ¸®Æ÷ÁöÅ丮ÀÇ °³¹ß·Î ¿¬±¸ÀÚ °£ °øµ¿ ¿¬±¸¸¦ ÃËÁøÇÏ°í ¸ÞŸºÐ¼®°ú Áý´Ü °£ ¿¬±¸°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ´ÜÀϼ¼Æ÷ ¸ÖƼ¿À¹Í½ºÀÇ ÃâÇöÀº ¼¼Æ÷ÀÇ ÀÌÁú¼ºÀ» ÀÌÇØÇÏ´Â ÇØ»óµµ¸¦ ´õ¿í ³ô¿© ¸é¿ªÇÐ, ¾Ï »ý¹°ÇÐ, ¹ß»ý »ý¹°Çп¡¼­ À¯¿ëÇÔÀ» ÀÔÁõÇϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ȹ±âÀûÀÎ ±â¼úÀÎ °ø°£ ¸ÖƼ¿À¹Í½º´Â ¿¬±¸ÀÚµéÀÌ Á¶Á÷ ³» ºÐÀÚ °£ »óÈ£ÀÛ¿ëÀ» °ø°£ÀûÀ¸·Î Á¤È®ÇÏ°Ô ¸ÅÇÎÇÏ¿© Áúº´ º´¸®Çп¡ ´ëÇÑ »õ·Î¿î ÀλçÀÌÆ®¸¦ Á¦°øÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ±×·¯³ª ¹èÄ¡ È¿°ú, ÀçÇö¼º ¹®Á¦, °è»ê ±â¹Ý °­È­ÀÇ Çʿ伺 µîÀÇ °úÁ¦°¡ ¿©ÀüÈ÷ º¸±ÞÀÇ À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ´Ù±â°ü °øµ¿ ¿¬±¸¿Í µ¥ÀÌÅÍ °øÀ¯ ÇÁ·¹ÀÓ¿öÅ©¸¦ ÃßÁøÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¹®Á¦¸¦ ¿ÏÈ­Çϰí, ¸ÖƼ¿À¹Í½º Á¶»çÀÇ ÀçÇö¼º°ú Åõ¸í¼ºÀ» ³ôÀÏ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¸ÖƼ¿À¹Í½º¿Í °è»ê ¸ðµ¨ÀÌ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ½Ã¹Ä·¹À̼ÇÇÏ´Â µðÁöÅÐ Æ®À© ±â¼ú°úÀÇ ÅëÇÕµµ ¸ÂÃãÇü ÀÇ·á ¹× Ä¡·á °³¹ß¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â À¯¸ÁÇÑ ºÐ¾ßÀÔ´Ï´Ù. ¸ÖƼ¿À¹Í½º°¡ °è¼Ó ÁøÈ­Çϸ鼭 ¾çÀÚ ÄÄÇ»ÅÍ, CRISPRÀ» ÀÌ¿ëÇÑ À¯ÀüÀÚ ÆíÁý, ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ µî ÷´Ü ºÐ¾ß¿ÍÀÇ ±³·ù°¡ ´Ã¾î³ª¸é¼­ °úÇÐÀû ¹ß°ß¿¡ »õ·Î¿î ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ¸ÖƼ¿À¹Í½º µ¥ÀÌÅ͸¦ ¿øÈ°ÇÏ°Ô ÅëÇÕÇÏ´Â ´É·ÂÀº ÀÌ ±â¼úÀÇ ÀáÀç·ÂÀ» ±Ø´ëÈ­Çϰí Áúº´ ±ËÀû°ú Ä¡·á ¹ÝÀÀÀ» º¸´Ù Á¤È®ÇÏ°Ô ¿¹ÃøÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¸ÖƼ¿À¹Í½º ¼¼°è ½ÃÀå ±Þ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

¼¼°è ¸ÖƼ¿À¹Í½º ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ½Å¾à °³¹ß¿¡¼­ÀÇ Ã¤Åà Áõ°¡, ¿À¹Í½º ±â¹Ý ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì(NGS), Áú·®ºÐ¼®, ÇÏÀ̽º·çDz ½ºÅ©¸®´× Ç÷§ÆûÀÇ ±Þ¼ÓÇÑ °³¹ß·Î Á¤È®µµ¿Í È®À强ÀÌ Çâ»óµÇ´Â µ¿½Ã¿¡ ºñ¿ëÀÌ Å©°Ô Àý°¨µÇ¾ú½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ¾÷°è´Â Á¤¹ÐÀÇ·á ÀÌ´Ï¼ÅÆ¼ºê¸¦ °¡¼ÓÈ­Çϰí, ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°À» °­È­Çϸç, ÀÓ»ó½ÃÇè¿¡¼­ ȯÀÚ ¼±ÅÃÀ» ÃÖÀûÈ­Çϱâ À§ÇØ ¸ÖƼ¿À¹Í½º¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ½Å°æÅðÇ༺ Áúȯ µî º¹ÀâÇÑ ÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸ÖƼ¿À¹Í½º¸¦ Ȱ¿ëÇÑ Áø´Ü ¹× Ä¡·áÁ¦ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸ÖƼ¿À¹Í½º¸¦ ÀΰøÁö´É ¹× ºòµ¥ÀÌÅÍ ºÐ¼®°ú ÅëÇÕÇÔÀ¸·Î½á, ƯÈ÷ Èñ±ÍÁúȯ ¹× ¸ÂÃãÇü ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸¿¡ º¥Ã³ ijÇÇÅаú Á¤ºÎ·ÎºÎÅÍ ¸¹Àº ÀÚ±ÝÀÌ À¯ÀԵǰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹Àº ÀǾàǰÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» Çâ»ó½ÃŰ´Â ¸ÖƼ¿À¹Í½ºÀÇ °¡Ä¡¸¦ Á¡Á¡ ´õ ÀνÄÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿À¹Í½º ±â¹Ý ÀÓ»ó½ÃÇè°ú µ¿¹ÝÁø´ÜÀ» Áö¿øÇÏ´Â À¯¸®ÇÑ Á¤Ã¥À¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ ´ë»ó À¯ÀüÀÚ °Ë»ç ȸ»ç¿Í ¸ÂÃãÇü °Ç°­ ÇÁ·Î±×·¥ÀÇ µîÀåÀ¸·Î ¸ÖƼ¿À¹Í½º Ȱ¿ëÀÇ »ó¾÷Àû Àü¸ÁÀº ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ó¾÷, ½Äǰ ¾ÈÀü, ȯ°æ ¸ð´ÏÅ͸µ ºÐ¾ß¿¡¼­ ¸ÖƼ¿À¹Í½º¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÎü °Ç°­ ÀÌ¿ÜÀÇ ºÐ¾ß¿¡¼­µµ ¸ÖƼ¿À¹Í½º µµÀÔÀÌ ÃËÁøµÇ¾î ½ÃÀå ´Ù°¢È­¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ºÐ¼®, ¹ÙÀÌ¿À¸¶Ä¿ °ËÁõ, Ŭ¶ó¿ìµå ±â¹Ý ÀÎÆ÷¸Åƽ½º Ç÷§Æû µî ¿£µå-Åõ-¿£µå ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ¸ÖƼ¿À¹Í½º ¼­ºñ½º Á¦°ø¾÷üÀÇ µîÀåÀ¸·Î ¸ÖƼ¿À¹Í½º ¿¬±¸´Â ÇÐ°è ¿¬±¸ÀÚ»Ó¸¸ ¾Æ´Ï¶ó »ê¾÷°è ¿¬±¸Àڵ鿡°Ôµµ ´õ¿í Ä£¼÷ÇØÁö°í ÀÖ½À´Ï´Ù. ´õ Ä£¼÷ÇØÁ³½À´Ï´Ù. ¸ÖƼ¿À¹Í½º ±â¼ú °³¹ßÀÚ, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü, Á¦¾à»ç °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀº Çõ½ÅÀ» ÃËÁøÇϰí, »ó¾÷È­¸¦ °¡¼ÓÈ­Çϸç, Áß°³ ¿¬±¸ ³ë·ÂÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ÇコÄÉ¾î »ê¾÷ÀÌ ¿¹¹æÀûÀ̰í Á¤¹ÐÇÑ Ä¡·á ¸ðµ¨·Î ÀüȯÇÏ´Â °¡¿îµ¥, ¸ÖƼ¿À¹Í½º´Â ¹Ì·¡ ÇコÄÉ¾î ÆÐ·¯´ÙÀÓ¿¡¼­ ÇʼöÀûÀÎ µµ±¸°¡ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¸ÖƼ¿À¹Í½º ±â¼úÀÇ ²÷ÀÓ¾ø´Â ¹ßÀü°ú ´Ù¾çÇÑ »ê¾÷ ºÐ¾ß¿¡¼­ÀÇ ÀÀ¿ë ºÐ¾ß°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¸î ³â µ¿¾È ¸ÖƼ¿À¹Í½º ½ÃÀåÀº ºñ¾àÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¹úÅ© ¸ÖƼ¿À¹Í½º, ´ÜÀϼ¼Æ÷ ¸ÖƼ¿À¹Í½º), Ç÷§Æû À¯Çü(À¯ÀüüÇÐ Ç÷§Æû, Àü»çüÇÐ Ç÷§Æû, ´Ü¹éÁúüÇÐ Ç÷§Æû, ´ë»çüÇÐ Ç÷§Æû, ÅëÇÕ ¿À¹Í½º Ç÷§Æû), ¿ëµµ(Á¾¾çÇÐ ¿ëµµ, ¼¼Æ÷»ý¹°ÇÐ ¿ëµµ, ½Å°æÇÐ ¿ëµµ, ¸é¿ªÇÐ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Çмú¡¤¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

ÀϹÝÀûÀ¸·Î ÁøÇàµÇ´Â LLM ¹× ¾÷°è ƯȭÇü SLM¿¡ ´ëÇÑ Äõ¸®¿¡ ÀÇÁ¸ÇÏ´Â ´ë½Å ¿ì¸®´Â ¼¼°è µµ¸ÞÀÎ Àü¹®°¡°¡ ¾ö¼±ÇÑ ÄÁÅÙÃ÷¸¦ Áý¾àÇÑ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù. ¿©±â¿¡´Â ºñµð¿À ³ìÃë·Ï, ºí·Î±×, °Ë»ö ¿£ÁøÀ» ÀÌ¿ëÇÑ Á¶»ç, ¹æ´ëÇÑ ±â¾÷ µ¥ÀÌÅÍ, Á¦Ç° ¹× ¼­ºñ½º Á¤º¸, ½ÃÀå µ¥ÀÌÅͰ¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

¿ì¸®´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç°°ú OEM)¿¡ µû¸¥ ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Multiomics Market to Reach US$7.4 Billion by 2030

The global market for Multiomics estimated at US$2.9 Billion in the year 2024, is expected to reach US$7.4 Billion by 2030, growing at a CAGR of 16.6% over the analysis period 2024-2030. Bulk Multiomics, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Single-Cell Multiomics segment is estimated at 14.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$769.1 Million While China is Forecast to Grow at 15.6% CAGR

The Multiomics market in the U.S. is estimated at US$769.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 15.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.5% and 14.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Multiomics Market - Key Trends & Drivers Summarized

How Is Multiomics Redefining Biological Insights and Precision Medicine?

Multiomics, an integrative approach combining genomics, transcriptomics, proteomics, epigenomics, and metabolomics, is revolutionizing biological research and clinical applications. By leveraging vast datasets across multiple biological layers, multiomics offers a deeper understanding of complex diseases, biological functions, and personalized medicine. Advances in sequencing technologies and high-throughput analytical tools have enabled researchers to study interactions between different molecular components with unprecedented precision. The integration of machine learning and artificial intelligence has further accelerated the interpretation of multiomics data, leading to breakthroughs in biomarker discovery, disease diagnostics, and therapeutic interventions. In oncology, multiomics is uncovering tumor heterogeneity and facilitating more targeted treatment regimens. Similarly, in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, multiomics enables a systems biology approach to uncover genetic and metabolic underpinnings. The pharmaceutical industry is actively adopting multiomics to enhance drug discovery, optimize clinical trial stratification, and predict patient responses to therapies. The advent of cloud computing and advanced bioinformatics tools has significantly improved the ability to store, analyze, and interpret multiomics data at scale, making it more accessible to researchers worldwide. Governments and healthcare institutions are increasingly funding large-scale multiomics initiatives, recognizing their potential to accelerate translational research. Despite these advancements, the field faces challenges related to data harmonization, standardization, and ethical considerations in data sharing. Nevertheless, with continuous innovation in computational biology and data integration frameworks, multiomics is poised to transform precision medicine and disease prevention strategies.

What Are the Emerging Applications and Industries Benefiting from Multiomics?

Beyond its role in precision medicine, multiomics is finding applications in diverse fields, including agriculture, microbiome research, nutrition science, and environmental monitoring. In agriculture, multiomics is being employed to enhance crop resilience, improve soil microbiomes, and develop genetically superior plant varieties that can withstand climate change-induced stressors. Microbiome research is leveraging multiomics to study complex microbial interactions in human health, agriculture, and industrial biotechnology. The application of metagenomics, proteomics, and metabolomics in gut microbiota studies has led to groundbreaking discoveries linking microbiome composition to diseases such as obesity, diabetes, and inflammatory disorders. In nutrition science, multiomics is paving the way for nutrigenomics, where personalized dietary recommendations are tailored based on an individual’s genetic and metabolic profile. The food and beverage industry is utilizing multiomics to optimize fermentation processes, improve probiotic formulations, and ensure food safety through advanced microbial profiling. Multiomics is also making significant contributions to environmental sciences by enabling researchers to monitor ecosystem biodiversity, track pollution effects, and study microbial communities in extreme environments such as deep-sea hydrothermal vents. The field of toxicology is increasingly integrating multiomics approaches to understand chemical exposures at the molecular level, improving risk assessments and regulatory frameworks. With advancements in synthetic biology, multiomics is facilitating the engineering of novel biomaterials, biofuels, and biopharmaceuticals, further expanding its industrial significance. The increasing interdisciplinary adoption of multiomics underscores its transformative impact across scientific and commercial sectors, driving innovation beyond traditional biomedical research.

Why Is Multiomics Data Integration Critical for Future Scientific Breakthroughs?

The integration of multiomics datasets remains one of the most challenging yet promising aspects of the field. The vast volume of data generated from multiomics studies requires sophisticated computational models capable of synthesizing insights across different biological layers. Recent advancements in AI-driven analytics, federated learning, and network-based modeling have improved multiomics data fusion, leading to more robust biomarker discovery and disease modeling. The standardization of data pipelines and the development of open-access repositories have facilitated greater collaboration among researchers, allowing for meta-analyses and cross-population studies. The emergence of single-cell multiomics has further enhanced resolution in understanding cellular heterogeneity, proving valuable in immunology, cancer biology, and developmental biology. Spatial multiomics is another breakthrough, enabling researchers to map molecular interactions within tissues with spatial precision, offering new insights into disease pathology. However, challenges such as batch effects, reproducibility issues, and the need for enhanced computational infrastructure remain barriers to widespread adoption. The push towards multi-institutional collaborations and data-sharing frameworks is expected to mitigate these challenges, fostering greater reproducibility and transparency in multiomics research. The integration of multiomics with digital twin technologies, where computational models simulate biological responses, is another promising frontier that could revolutionize personalized medicine and therapeutic development. As multiomics continues to evolve, it is increasingly intersecting with other cutting-edge fields such as quantum computing, CRISPR-based genome editing, and bioprinting, opening new avenues for scientific discovery. The ability to seamlessly integrate multiomics data will be crucial in unlocking the full potential of this technology, enabling more accurate predictions of disease trajectories and treatment responses.

What Is Driving the Rapid Growth of the Global Multiomics Market?

The growth in the global multiomics market is driven by several factors, including technological advancements, rising adoption in drug discovery, and increased funding for omics-based research. The rapid development of next-generation sequencing (NGS), mass spectrometry, and high-throughput screening platforms has significantly reduced costs while improving accuracy and scalability. The pharmaceutical and biotechnology industries are heavily investing in multiomics to accelerate precision medicine initiatives, enhance biomarker identification, and optimize clinical trial patient selection. The increasing incidence of complex diseases, including cancer, autoimmune disorders, and neurodegenerative conditions, is further fueling demand for multiomics-driven diagnostics and therapeutics. The integration of multiomics with artificial intelligence and big data analytics is attracting substantial venture capital and government funding, particularly for research focused on rare diseases and personalized healthcare solutions. Regulatory agencies are increasingly recognizing the value of multiomics in improving drug safety and efficacy, leading to favorable policies supporting omics-based clinical trials and companion diagnostics. The rise of direct-to-consumer genetic testing companies and personalized wellness programs is further expanding the commercial landscape for multiomics applications. Moreover, the growing emphasis on multiomics in agriculture, food safety, and environmental monitoring is driving its adoption beyond human health, contributing to market diversification. The emergence of multiomics service providers offering end-to-end solutions, including data analysis, biomarker validation, and cloud-based informatics platforms, is making multiomics research more accessible to academic and industrial researchers alike. Strategic partnerships between multiomics technology developers, healthcare providers, and pharmaceutical companies are fostering innovation, accelerating commercialization, and enhancing translational research efforts. As the global healthcare industry shifts towards preventive and precision-based treatment models, multiomics is set to become an indispensable tool in future healthcare paradigms. With continuous advancements in multiomics technologies and their increasing applications across multiple industries, the market is poised for exponential growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Multiomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Bulk Multiomics, Single-Cell Multiomics); Platform Type (Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform, Integrated Omics Platforms); Application (Oncology Application, Cell Biology Application, Neurology Application, Immunology Application); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â